> CordenPharma Chenôve (FR) completes €35m Phase 2 investment with the inauguration of new small molecule and lipid development, manufacturing and purification facilities. On Monday 2 September, CordenPharma Chenôve Managing Director James Leresche, the site Leadership team (Virginie HILAND, Jocelyne breval, Beatrice LUCAS, André SEMERIE, Sebastien Rose, Charles Leslie DEGILA) and Project Manager Cyril BECAT were joined by CordenPharma CEO Dr. Michael Quirmbach, COO Dr. Lee Newton, Chief Quality & Compliance Officer William Cashin, Chief Commercial Officer Dr. Stephan Haitz and CFO Gary Hughes to inaugurate the completion of the expansion assets for lipids and small molecules at the site. The day began with a breakfast for all employees, followed by executive leadership remarks and an inauguration ceremony in the new synthesis building with key team players on the project. The expansion completed phase 2 of an overall investment started in 2021 after the French Government launched a “Capacity Building” program called AMI (Appel à Manifestation d’Intérêt) to support and boost the industrialization of health products in France. Phase 1, completed in 2022, included the renovation of an R&D laboratory and the addition of several analytical instruments, a GMP mid-scale purification unit, and a newly-hired, focused team of experts. Phase 2 includes the design and construction of a larger GMP manufacturing facility at CordenPharma Chenôve, with a manufacturing concept which increases production capacity to provide customers with multi metric tons of small molecules and lipids using modern chemical reaction, isolation and purification equipment and, in particular, sustainable and innovative Supercritical Fluid Chromatography (SFC) technology, thus reducing supply chain environmental footprint. New expansion features include 6 m3 reactors, agitated filter dryers and centrifuges, the installation of 76 mm and 220 mm SFC technology, and a skid for hydride chemistry, as well as a new warehouse (-20°, 5°C and +20 °C), and storage tank farm extensions for improved storage conditions. The additions not only increase capacity but allow for future pipeline growth. Michael Quirmbach comments, “The completion of this strategic investment will augment our robust lipid and small molecule platforms to support innovators with the complex modalities and sustainable technologies they need for the development and commercialization of LNP-based xRNA and other small molecule therapeutics.” #CordenPharma #francepharma #greenchemistry #purification #lipids #lnps #mrna #pharmamanufacturing #sfc #smallmolecules #pharmaceuticals
Corden Pharma - A Full-Service CDMO
Arzneimittelherstellung
Basel, BS 35.638 Follower:innen
The partner you need.
Info
CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com
- Website
-
https://www.cordenpharma.com
Externer Link zu Corden Pharma - A Full-Service CDMO
- Branche
- Arzneimittelherstellung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Basel, BS
- Art
- Privatunternehmen
- Gegründet
- 2006
- Spezialgebiete
- Contract Development & Manufacturing Organization (CDMO), Sterile Injectable Drug Products, Aseptic Fill & Finish, Oligonucleotides, Lipid Excipients, LNP Formulation, Peptides, LNP Formulation, Highly Potent APIs & Drug Products und Small Molecule Drug Dosage Forms
Orte
Beschäftigte von Corden Pharma - A Full-Service CDMO
Updates
-
Today, as we celebrate World Charity Day, we couldn’t think of a better way to honor it than by sharing our concrete actions within our community. At CordenPharma, our commitment to giving back to society is part of who we are. This summer, our dedication had special meaning as we combined our summer events with a specific focus: contributing to a healthcare organization with a symbolic donation for each of our employees We proudly supported several healthcare organizations ( LILT SEZIONE BERGAMO Epilepsie-France, Community Foundation Boulder County, Schweizerische Morbus Crohn / Colitis Ulcerosa Vereinigung, Hilfe für krebskranke Kinder Frankfurt e. V., LIGUE FRIBOURGEOISE CONTRE LE CANCER, Kinderspitex Nordwestschweiz, Seltene Krankheiten – Förderverein für Kinder mit seltenen Krankheiten Schweiz, Maria Letizia Verga Centre , Portuguese Inflammatory Disease Association of the intestine, CLARA - Ecumenical Children's and Youth Hospice Service- Mannheim), selected by our sites, by making donations that target a variety of diseases. These contributions are closely aligned with our business focus areas and reflect our commitment to improving health outcomes worldwide. By integrating these charitable actions into our summer events, we brought our team together with a shared purpose—making a real difference in the lives of others. Our summer initiative was more than just a series of events; it was a reflection of our values in action. Through our donations, we’ve not only strengthened our ties to the community but also enhanced our team spirit and working culture. We are very proud of what we’ve accomplished together as One CordenPharma. When we come together with passion and purpose, we can achieve incredible things. Thanks to all our employees for being part of this journey! #cordenpharma #CDMO #worldcharityday #corporateresponsibility #givebacktosociety
-
We would like to welcome, Christian Merz, Managing Director, CordenPharma Plankstadt, to the CordenPharma team! #cordenpharma #cdmo #leadership #drugproducts #pharmamanufacturing #pharmaceuticals
-
Attending the PDA/FDA Joint Regulatory Conference 2024 in Washington? Visit us at booth 310! Our team will be there to discuss our bespoke end-to-end solutions, covering all stages from drug development to commercialization. #cordenpharma #pdafda #cdmo #pharma #pharmaceuticals #pharmaindustry #drugdevelopment
-
We would like to welcome Michael Landau, Managing Director, CordenPharma Colorado, to the CordenPharma team! #cordenpharma #colorado #cdmo #leadership #apis #pharmaceuticals #pharmamanufacturing #peptides #hpapis
-
Visit us at ChemOutsourcing from September 3rd to 6th! Our team will be at booth #45, ready to answer all your questions about how we can support your drug development lifecycle at all stages, from sourcing of raw materials to secure your supply chain, through preclinical & commercial development and manufacturing of GMP starting materials, APIs, Lipid excipients, Lipid NanoParticles (LNPs), finished dosage drug products, Packaging and final distribution. #cordenpharma #chemoutsourcing2024 #cdmo #pharma #pharmaceuticals #drugdevelopment #drugproduct #apis
-
Join us at the Peptides Therapeutics Forum in Basel on August 22nd and 23rd - booth number 1 Don't miss out our poster presentation titled 'Flow – SPPS towards greener and more efficient peptide manufacturing' by Senior Scientist Oliver Kracker. #cordenpharma #cdmo #peptides #pharmaceuticals #pharmaindustry #drugdevelopment
-
> CordenPharma Lisbon (PT) inaugurates a new oral solid dosage tablet coating equipment upgrade in Manufacturing Unit 1! On 30th of July, CEO Dr. Michael Quirmbach and Chief Commercial Officer Dr. Stephan Haitz joined CordenPharma Lisbon Site Managing Director Rosário Fonseca, HR & Legal Director Isilda Serra, Production Director Margarida D. Henriques Henriques, Maintenance & Engineering Lead Vasco Dias, along with Site Project Teams and Unit Operators to hold an inauguration ceremony. This new cutting-edge coating equipment (Hütllin, Sepion 250) allows the Lisbon site to manufacture coated tablets, in addition to the uncoated tablets previously offered. Driven by our strategic decision to address the market demand and customer preference for coated tablets, the benefits of the new capability include important characteristics such as controlled release, taste masking, and greater protection of the Active Pharmaceuticals Ingredients (APIs) they contain. The installation and qualification of CordenPharma Lisbon’s new coating equipment took place in June 2024 and will go live in August 2024. CEO Michael Quirmbach kicked off the ceremony with a brief speech on the significance of the equipment upgrade, both in terms of its benefits to our customers, and in strengthening CordenPharma’s overall integrated offerings. He commented on the hard work by site Leaders, Project Teams and Operators involved in bringing this important project to reality, and the future opportunities that it drives for CordenPharma. The highlight of the inauguration was a ribbon cutting, followed by a delicious lunch buffet, allowing a well-deserved moment for all employees involved to celebrate this important technological upgrade for the Lisbon site. #CordenPharmaLisbon #tablets #coatedtablets #oralsoliddose #pharmaceuticals #drugproducts #pharmamanufacturing #controlledrelease #tastemasking #cdmo
-
Mimoun Ayoub, Ph.D., Sr. VP of Sales and Key Account Management, gives a video update at Tides US 2024 on key trends in the Tides CDMO space, and how CordenPharma is addressing them with the supply of complex modalities, such as peptides, lipids, and oligonucleotides, and integrated services like GMP Lipid NanoParticle Formulation, LNP Starter Kits and clinical to commercial supply of sterile injectable Drug Products. #cordenpharma #cdmo #tides #peptides #lipids #oligonucleotides #injectables #lnps #drugdevelopment #pharma #pharmaceuticals
-
Learn more about our LNP Manufacturing Services. Our new cGMP Lipid NanoParticle (LNP) manufacturing facility in Caponago, Italy, is FDA and EMA approved. Building on decades of sterile injectable experience, it fully supplements our existing LNP development capabilities. The 900 m² suite is state-of-the-art, Grade C throughout, fully scalable, and offers process and purification scale-up, including the following technologies and services: -A full variety of nanoparticle assembly systems, notably Impingement Jets Mixing (IJM) by Knauer and NxGen Microfluidic technology by Cytiva -A wide selection of purification technologies such as Ultrafiltration (UF), Diafiltration (DF) and Tangential Flow Filtration (TFF) - Comprehensive analytical services As part of our fully-integrated offering CordenPharma additionally offers Aseptic Fill & Finish services conveniently located under the same roof, as well as a wide selection of functional Lipid Excipients provided within the CordenPharma facility network. https://lnkd.in/d8EdQ_bf #CordenPhama #CDMO #LNP #lipidnanoparticles #pharmaceuticals #pharma #pharmaindustry #injectables